- Home
- PGRE vs EVO Comparison
PGRE vs EVO Comparison
Compare PGRE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- EVO
- Stock Information
- Founded
- PGRE 1978
- EVO 1993
- Country
- PGRE United States
- EVO Germany
- Employees
- PGRE N/A
- EVO N/A
- Industry
- PGRE Real Estate Investment Trusts
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- EVO Health Care
- Exchange
- PGRE Nasdaq
- EVO Nasdaq
- Market Cap
- PGRE 1.4B
- EVO 1.2B
- IPO Year
- PGRE 2014
- EVO 2021
- Fundamental
- Price
- PGRE $7.12
- EVO $3.47
- Analyst Decision
- PGRE Hold
- EVO Buy
- Analyst Count
- PGRE 4
- EVO 2
- Target Price
- PGRE $5.55
- EVO $5.40
- AVG Volume (30 Days)
- PGRE 2.7M
- EVO 45.6K
- Earning Date
- PGRE 10-29-2025
- EVO 11-05-2025
- Dividend Yield
- PGRE N/A
- EVO N/A
- EPS Growth
- PGRE N/A
- EVO N/A
- EPS
- PGRE N/A
- EVO N/A
- Revenue
- PGRE $701,980,000.00
- EVO $912,894,891.00
- Revenue This Year
- PGRE $1.41
- EVO $0.43
- Revenue Next Year
- PGRE N/A
- EVO $9.72
- P/E Ratio
- PGRE N/A
- EVO N/A
- Revenue Growth
- PGRE 35.23
- EVO N/A
- 52 Week Low
- PGRE $3.75
- EVO $2.84
- 52 Week High
- PGRE $7.55
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- PGRE 55.61
- EVO 41.34
- Support Level
- PGRE $7.07
- EVO $3.40
- Resistance Level
- PGRE $7.33
- EVO $3.55
- Average True Range (ATR)
- PGRE 0.21
- EVO 0.07
- MACD
- PGRE -0.02
- EVO 0.02
- Stochastic Oscillator
- PGRE 55.38
- EVO 42.31
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.